Synthetic Peptides as Antigens (eBook)
380 Seiten
Elsevier Science (Verlag)
978-0-08-085897-5 (ISBN)
It gives background information on antigenic specificity, prediction of antigenic sites in proteins and applications of peptides in immunology and virology, as probes in diagnosis and as vaccines. The book also describes antigenicity of proteins and methods to localize antigenic sites as well as methods for predicting epitoxes, and gives detailed protocols for peptide-carrier conjugation, immunization with peptides, and peptide immunoassays.
The volume also describes typical use of antipeptide antibodies in molecular and cellular biology as well as the use of peptides in the diagnosis of viral infections and autoimmune diseases, and the use of peptides as potential synthetic vaccines. An excellent edition to an excellent series, available in hardbound and paperback.
This newest edition to the Laboratory Techniques Series gives current state of the art use of synthetic peptides in molecular biology and practical protocols on how to conjugate peptides, immunize animals with peptides and monitor immune responses to peptides in vitro. It gives background information on antigenic specificity, prediction of antigenic sites in proteins and applications of peptides in immunology and virology, as probes in diagnosis and as vaccines. The book also describes antigenicity of proteins and methods to localize antigenic sites as well as methods for predicting epitoxes, and gives detailed protocols for peptide-carrier conjugation, immunization with peptides, and peptide immunoassays. The volume also describes typical use of antipeptide antibodies in molecular and cellular biology as well as the use of peptides in the diagnosis of viral infections and autoimmune diseases, and the use of peptides as potential synthetic vaccines. An excellent edition to an excellent series, available in hardbound and paperback.
Front Cover 1
Synthetic Peptides as Antigens 4
Copyright Page 5
Contents 12
Acknowledgements 6
List of abbreviations 8
Chapter 1. Molecular dissection of protein antigens and the prediction of epitopes 20
1.1. Introduction 20
1.2. Definition of antigenicity and the concept of epitope 22
1.3. Types of epitopes 29
1.4. Methods used for localizing epitopes 36
1.5. The antigenic structure of model proteins 58
1.6. Antigenicity prediction 72
1.7. T-cell epitopes 88
Chapter 2. Peptide-carrier conjugation 98
2.1. Introduction 98
2.2. Choice of carrier 99
2.3. Optimal peptide density on carrier protein 102
2.4. Point of attachment on peptide chain 104
2.5. Chemical coupling 104
2.6. Photochemical coupling 128
2.7. Coupling of peptides to liposomes 133
2.8. Coupling of peptides to solid supports 138
2.9. Determination of peptide: carrier ratio of conjugates 145
2.10. Peptide derivatization 148
Chapter 3. Immunization with peptides 152
3.1. Introduction 152
3.2. The choice of animal 153
3.3. The immunogen 155
3.4. The adjuvant 177
3.5. The route of injection 186
3.6. Specific immunization protocols 188
3.7. Concluding remarks 196
Chapter 4. Peptide immunoassays 198
4.1. Introduction 198
4.2. Types of solid-phase immunoassays 200
4.3. Solid-phase immunoassay procedures 215
4.4. Dot immunobinding assay 221
4.5. Spotscan assay 222
4.6. Biosensor assays 223
4.7. Measurement of affinity constants 229
4.8. Monitoring of the immune response to peptides 231
Chapter 5. Use of antipeptide antibodies in molecular and cellular biology 234
5.1. Detection of gene products with antipeptide antibodies 234
5.2. Use of antipeptide antibodies in immunohistochemistry and immunocytochemistry 251
Chapter 6. The use of peptides for diagnosing viral infections 256
6.1. Mimicry of viral epitopes with synthetic peptides 256
6.2. Synthetic peptides for viral diagnosis 261
6.3. Peptide-based immunoassays 263
Chapter 7. Peptides in diagnosis of autoimmune diseases 266
7.1. Introduction 266
7.2. Methods of detection and quantification of autoantibodies with synthetic peptides 267
7.3. Specific examples of autoepitope mapping data 281
7.4. Prediction of epitopes recognized by autoantibodies 292
7.5. Peptides mimicking sites of post-translational modification recognized by autoantibodies 297
7.6. Concluding remarks 298
Chapter 8. Synthetic peptides as vaccines 300
8.1. Introduction 300
8.2. Antiviral vaccines 303
8.4. Vaccines against parasites 330
8.5. Are molecular design strategies applicable to the development of synthetic vaccines? 332
8.6. Empirical discovery rather than molecular design will bring about new synthetic vaccines 333
References 338
Subject Index 394
Peptide-carrier conjugation
S. Muller
2.1 Introduction
Most authors agree that in order to produce antibodies against small peptides of molecular ratio (ΜΓ) 700–1500, it is necessary to enhance their immunogenicity by coupling them to protein carriers (see Butler and Beiser, 1973). Furthermore, when short peptides are used as the immobilized antigen in solid-phase immunoassays, it is either necessary to modify the peptide (Loomans et al., 1997), or use peptide-carrier conjugates, since peptides of 6–15 residues generally do not bind satisfactorily to plastic surfaces.
The different coupling procedures that have been used to prepare peptide-carrier conjugates are listed in Table 2.1. In many instances, the chemistry of these conjugation reactions has not yet been elucidated. The aim of this chapter is to describe the different techniques in such a way that the investigator is able to choose the most appropriate procedure for his particular peptide. The choice of conjugation procedure is important since the antigenic activity of a peptide may be drastically affected by different coupling procedures (Briand et al., 1992b). The coupling of small molecules to carriers has many applications outside immunology (Pique et al., 1978; Talamo et al., 1968; Widder and Green, 1985). Several comprehensive reviews dealing with chemical modifications of proteins can be consulted to obtain information on the types of chemical intermolecular bridges that can be introduced into proteins (Atassi, 1977a; Boersma et al., 1993; Erlanger, 1980; Feeney et al., 1982; Glazer et al., 1975; Han et al., 1984; Hermanson, 1996; Kiefer, 1979; Means and Feeney, 1995; Peters and Richards, 1977; Rongen et al., 1997; Thorell and Larson, 1978).
Table 2.1
Principal reagents used for peptide-protein conjugation a
Glutaraldehyde | ε-NH2, α-NH2, SH-Cys | Tyr, His | Habeeb and Hiramoto (1968) |
Bisimido esters (DMA, DMS …) | α-NH2, ε-NH2Lys | Negligible | Means and Feeney (1971) |
BDB | Tyr, SH-Cys, His ε-NH2Lys | Trp, Arg | Glazer et al. (1975) |
Carbodiimides (EDC, MCDI…) | α-NH2, ε-NH2Lys α-COOH, Glu, Asp | Tyr, Cys | Goodfriend et al. (1964) |
MBS | Cys-SH, NH2 bridgs | n.o. | Kitagawa and Aikawa (1976) |
SPDP, MCS | Cys-SH, NH2 bridgs | n.o. | Carlsson et al. (1978); Lee et al. (1980) |
Imido esters (2-iminothiolane) | Cys-SH, NH2 bridgs | n.o. | King et al. (1978) |
IBCF | –COOH, NH2 bridgs | n.o. | Thorell and Larson (1978) |
Toluene diisocyanate | α-NH2, ε-NH2,Lys | n.o. | Talamo et al. (1968) |
p-nitrobenzone chloride | Tys, His, SH-Cys, ε-NH2Lys | Trp, Arg | Anderer and Schlumberger (1965b) |
p-amino phenyl acetic acid | α-NH2, ε-NH2,Lys | His, Tyr | Spirer et al. (1977) |
Cystamine dihydrochloride | SH-Cys | n.o. | Gilliland and Collier (1980) |
EBIZ | α-NH2, ε-NH2,Lys, –COOH | n.o. | Likhite and Sehon (1967) |
Periodate oxidation | N-terminal Ser and Thr | Cys | Geoghegan and Stroh (1992); Zhang and Tam (1996) |
a For abbreviations, see text, and list, p. vii. n.0. = Not observed.
Most procedures for preparing peptide-protein conjugates are based on the use of symmetrical or asymmetrical bifunctional reagents which either become incorporated into the final conjugate or activate certain reactive sites of the carrier protein molecule for subsequent linkage with the peptide. During the coupling reaction inter- but also intramolecular bridging can take place. Several factors such as protein concentration, ratio of coupling agent to protein, ionic strength and pH govern the kind of linkage obtained in the final product. For example, at low concentration of reactants, unwanted intramolecular linking reactions often predominate.
Although a wide range of coupling reagents has been reported in the literature, nearly all of them react primarily with the ε-amino group of lysine and the nucleophilic thiol of cysteine and only secondarily with the imidazole group of histidine and the phenolic hydroxyl group of tyrosine (Tables 2.1, 2.2). Only a few compounds such as bisimido esters are group-specific protein reagents.
Table 2.2
Functional groups in proteins used in peptide-carrier conjugation
2.2 Choice of carrier
Carrier molecules are chosen on the basis of criteria such as availability of reactive sites, size, solubility, immunogenicity, commercial availability and cost. The most commonly used carriers are listed in Table 2.3. One of the most important parameters that determines the suitability of a particular carrier molecule is the solubility of the final conjugate, since this may influence the accessibility of antigenic sites. When using the same coupling agent and peptide, some carriers may give insoluble conjugates while others give rise to soluble conjugates. Certain carriers are preferable when the peptide-carrier ratio is to be determined by amino acid analysis. Keyhole limpet haemocyanin (KLH), for instance, is not appropriate in this case since it has a high molecular weight and commercial preparations usually contain many impurities. In our laboratory, we use bovine serum albumin (BSA) for preparing peptide conjugates intended for use as antigens, and ovalbumin for preparing conjugates to be used for immunization. When this combination of carriers is used, BSA can be included as blocking agent in immunoassays without interference by the antiovalbumin antibodies present in the antipeptide-carrier antiserum.
Table 2.3
Principal carriers used for coupling peptides
Bovine serum albumin | BSA | 67 | 59b | 35 | 19 | 17 | (1) |
Oval bumin | OVA | 43 | 20 | 6 | 10 | 7 | (2) |
Myoglobin | – | 17 | 19 | 0 | 3 | 12 | (1) |
Tetanus toxoid | TT | 150 | 106 | 10 | 81 | 14 | (3) |
Keyhole limpet haemocyaninc | KLH | > 8000 | 6.9 | 1.7 | 7.0 | 8.7 | (4) |
a Other carriers have also been used such as thyroglobulin (669 kD). diphtheria toxoid, rabbit serum albumin, bovine or mouse γ-globulin (150 kD), poly (l-lysine) (15–300 kD), poly (L-glutamic acid) (15–100 kD), dipalmityl lysine, ficoll(40 kD) (Boyle et al., 1983: Fok et al., 1982; Hopp, 1984a; Lee et al., 1980; Talamo et al., 1968; Wheat et al., 1985).
b Only 30–35 of the 59 lysine residues of BSA are accessible.
c For KLH, the amino acid composition is expressed in g amino acid/100 g.
d References: (1) Dayhoff (1976); (2) Nisbet et al. (1981): (3) Bizzini et al. (1970); (4) Malley el al. (1965).
Apart from presenting the peptide in a polyvalent fashion, the carrier can also exert an effect on the structure of the associated peptide and hence on its immunogenicity and antigenicity (Bahraoui et al., 1986b; Friede et al., 1994; Mariani et al., 1987). According to the point of attachment of the peptide to the carrier and the electrostatic and hydrophobic environment of this site, peptides can adopt different structures. In this regard, the use of liposomes as carrier of peptides presents several advantages over the protein constructs in that the surface of the liposome being uniform, it is probable that carrier effects on the structure of the peptide will be uniform (Friede et al., 1993c, 1994).
2.3...
Erscheint lt. Verlag | 25.11.1999 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete |
Studium ► 2. Studienabschnitt (Klinik) ► Anamnese / Körperliche Untersuchung | |
Studium ► Querschnittsbereiche ► Infektiologie / Immunologie | |
Naturwissenschaften ► Biologie ► Biochemie | |
Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie | |
Technik | |
ISBN-10 | 0-08-085897-X / 008085897X |
ISBN-13 | 978-0-08-085897-5 / 9780080858975 |
Haben Sie eine Frage zum Produkt? |
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich